Abstract:Embryonic stem cell pathways such as hedgehog and Wnt pathways are central to the tumorigenic properties of cancer stem cells (CSC). Since CSCs are characterized by their ability to self-renew, form differentiated progeny, and develop resistance to anticancer therapies, targeting the Wnt and hedgehog signaling pathways has been an important strategy for cancer treatment. Although molecules targeting either Wnt or hedgehog are common, to the best of our knowledge, those targeting both pathways have not been documented. Here we report a small molecule (compound 1) that inhibits both Wnt (IC50 = 0.5 nM) and hedgehog (IC50 = 71 nM) pathways based on reporter gene assays. We further identified that the molecular target of 1 for Wnt pathway inhibition was porcupine (a member of the membrane-bound O-acyltransferase family of proteins), a post-translational modification node in Wnt signaling; while the target of 1 mitigating hedgehog pathway was Smoothened, a key G protein coupled receptor (GPCR) mediating hedgehog signal transduction. Preliminary analysis of structure-activity-relationship identified key functional elements for hedgehog/Wnt inhibition. In in vivo studies, compound 1 demonstrated good oral exposure and bioavailability while eliciting no overt toxicity in mice. An important consideration in cancer treatment is the potential therapeutic escape through compensatory activation of an interconnected pathway when only one signaling pathway is inhibited. Toward this end, compound 1 may not only lead to the development of new therapeutics for Wnt and hedgehog related cancers, but may also help to develop potential cancer treatment which needs to target Wnt and hedgehog signaling simultaneously.

Ultra-large scale virtual screening identifies a small molecule inhibitor of the Wnt transporter Wntless

Discovery of Potential WEE1 Inhibitors Via Hybrid Virtual Screening

Discovery of Novel Inhibitor for WNT/-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Identification of Potential WSB1 Inhibitors by AlphaFold Modeling, Virtual Screening, and Molecular Dynamics Simulation Studies

Inhibiting The Wnt Signaling Pathway With Small Molecules

C644‐0303, a small‐molecule inhibitor of the Wnt/β‐catenin pathway, suppresses colorectal cancer growth

Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer

Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled

Small Molecule–mediated Disruption of Wnt-dependent Signaling in Tissue Regeneration and Cancer

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Drug discovery efforts toward inhibitors of canonical Wnt/13-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010-2020)

Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity

Synthesis of Potent Dishevelled PDZ Domain Inhibitors Guided by Virtual Screening and NMR Studies

Discovery of 2-(3-(3-carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives As Novel Small-Molecule Inhibitors of the Β-Catenin/b-cell Lymphoma 9 Protein–Protein Interaction

Effective Virtual Screening Strategy Toward Covalent Ligands: Identification of Novel NEDD8-Activating Enzyme Inhibitors

Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with <i>in vivo</i> antitumor activity

Discovery of Novel CDK8 Inhibitors Using Multiple Crystal Structures in Docking-Based Virtual Screening

Discovery and Characterization of a Potent Wnt and Hedgehog Signaling Pathways Dual Inhibitor.